Remove 2022 Remove Data Remove Safety
article thumbnail

Canopy Growth Reports First Quarter Fiscal 2022 Financial Results – The John Bonham Of Cannabis?

Cannabis Law Report

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105
article thumbnail

Positive Cannabis Drug Tests in the Workplace at the Highest in 25 years

Veriheal

A recent Quest Diagnostics Drug Testing Index Analysis revealed that positive post-accident drug tests of workers reached an all-time high in 2022. Quest Diagnostics started analyzing yearly workplace drug testing data 25 years ago in 1988, and the result of their recent study was published on May 18. Based on the report, 7.3%

Safety 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CBD Market Report

Project CBD

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144
article thumbnail

Analysis: Propagation of Cannabis Retailers Not Associated with Changes in Traffic Safety

Cannabis Law Report

POSTED ON AUGUST 18, 2022. La Jolla, CA: The establishment of licensed cannabis retailers is not independently associated with an increase in traffic crashes, according to data published in the journal Health Economics.

Safety 52
article thumbnail

US Hemp Roundtable: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

Cannabis Law Report

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study was completed on March 22, 2022, and involved 1,061 participants, providing a 98% power rating on its results, which is statistically significant. The methods for both phases were the same.

Safety 52
article thumbnail

US Hemp Round Table: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

Cannabis Law Report

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.

Safety 52
article thumbnail

Announcement: California Department of Cannabis Control Debuts Data Tool Showcasing Access Areas for Cannabis Business

Cannabis Law Report

This data helps Californians understand the work we have ahead of us in realizing the promises of cannabis legalization, including supporting access to a safe, legal, and equitable cannabis market across the state and combating the unregulated, illicit market”. The data tool can be found on the DCC website here: [link]. Tweet this.

Data 52